Factors Influencing the Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Single Institution Results from Saudi Arabia

Abstract

Medical records of 73 patients with AML who underwent HCT, 2005-2011. The OS was 51.8% and the EFS were 48%. Median follow-up time for the cohort was 50.667 ± 2.4 months (95%CI: 45.9-55.4). 39 patients were alive with a median follow-up time of 50.1 months (Min: 1.8, Max: 111.8). Sixteen patients survived for more than 5 years (Min: 65.2, Max: 111.8 months). The cumulative incidence of acute GVHD was 6.8 ± 2.9 and of chronic GVHD was 9.9 ± 3.6. Median time to ANC and platelet recovery was 16 days (range 9-37) and 29 days (range 15-180) respectively. Three patients acquired CMV infection after transplant. There was a significant impact of patient’s age at diagnosis on the overall survival (Infantile: 100%, others: 45.6% ± 6.4%, P=0.016) and event free survival (Infantile: 100%, others: 40.6% ± 7.1%, P=0.013). Percentage of blasts at transplant, patients or donors gender, donor source and HLA disparity did not significantly affect OS or EFS.